Who Owns Sanofi?

Sanofi Genzyme's oral disease-modifying therapy (teriflunomide) for relapsing forms of multiple sclerosis, FDA approved September 12, 2012, that works by inhibiting dihydroorotate dehydrogenase (DHODH) to selectively reduce proliferating lymphocytes driving MS inflammation.

Bivalent HPV vaccine targeting HPV types 16 and 18, developed by GSK. Discontinued in most markets as part of GSK portfolio rationalization.

Blockbuster biologic medication (dupilumab) co-developed by Sanofi and Regeneron Pharmaceuticals. FDA approved in 2017. Over 1.4 million active patients worldwide. Global net sales of $17.8 billion in 2025.

Prescription chemotherapy medication (oxaliplatin) for treating colorectal cancer, owned by Sanofi (Euronext Paris: SAN / NASDAQ: SNY). Approved by the FDA in 2002. Now available as a generic following patent expiration.

Sanofi's long-acting insulin glargine for type 1 and type 2 diabetes, FDA approved April 2000, that reached peak global sales of $6.4 billion in 2015 before biosimilar competition eroded its market share.

Sanofi Genzyme's high-efficacy anti-CD52 monoclonal antibody (alemtuzumab) for active relapsing-remitting multiple sclerosis, FDA approved November 14, 2014, reserved for patients with inadequate response to two or more disease-modifying therapies due to its serious risk profile and REMS program.